{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:56:19Z","timestamp":1790034979455,"version":"4.0.1"},"reference-count":23,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":3817,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To explore whether treatment with pioglitazone was associated with risk of incident cancer at the 10 most common sites (prostate, female breast, lung\/bronchus, endometrial, colon, non-Hodgkin lymphoma [NHL], pancreas, kidney\/renal pelvis, rectal, and melanoma).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>A cohort study of 252,467 patients aged \u226540 years from the Kaiser Permanente Northern California Diabetes Registry was conducted. All prescriptions for diabetes medications were identified by pharmacy records. Cox proportional hazards models were used to examine the association between risk of incident cancer and ever use, duration, dose, and time since initiation of pioglitazone (modeled as time-dependent variables).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>In models adjusted for age, sex, year of cohort entry, race\/ethnicity, income, smoking, glycemic control, diabetes duration, creatinine levels, congestive heart failure, and use of other diabetes medications, the hazard ratio (HR) for each cancer associated with ever use of pioglitazone ranged from 0.7 to 1.3, with all 95% CIs including 1.0. There was a suggestion of an increased risk of melanoma (HR 1.3 [95% CI 0.9\u20132.0]) and NHL (1.3 [1.0\u20131.8]) and a decreased risk of kidney\/renal pelvis cancers (0.7 [0.4\u20131.1]) associated with ever use of pioglitazone. These associations were unaltered with increasing dose, duration, or time since first use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>We found no clear evidence of an association between use of pioglitazone and risk of the incident cancers examined. Because the maximum duration of follow-up was fewer than 6 years after the initiation of pioglitazone, longer-term studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc10-1067","type":"journal-article","created":{"date-parts":[[2011,3,29]],"date-time":"2011-03-29T17:39:40Z","timestamp":1301420380000},"page":"923-929","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":158,"title":["Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes"],"prefix":"10.2337","volume":"34","author":[{"given":"Assiamira","family":"Ferrara","sequence":"first","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Center for Education and Research in Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Department of Medicine, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Charles P.","family":"Quesenberry","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Peng","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Strom","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Center for Education and Research in Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Department of Medicine, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Van Den Eeden","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha F.","family":"Ehrlich","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel A.","family":"Habel","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2011,3,21]]},"reference":[{"key":"2022031302493478200_B1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031302493478200_B2","first-page":"2170","article-title":"Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells","volume":"86","author":"Ohta","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031302493478200_B3","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1073\/pnas.95.15.8806","article-title":"Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice","volume":"95","author":"Elstner","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022031302493478200_B4","first-page":"3593","article-title":"Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis","volume":"28","author":"Takano","year":"2008","journal-title":"Anticancer Res"},{"key":"2022031302493478200_B5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/pmj.2006.052761","article-title":"Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells","volume":"83","author":"Shen","year":"2007","journal-title":"Postgrad Med J"},{"key":"2022031302493478200_B6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1023366117157","article-title":"PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro","volume":"79","author":"Liu","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"2022031302493478200_B7","first-page":"47","article-title":"Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3","volume-title":"BMC Cancer","author":"Magenta","year":"2008"},{"key":"2022031302493478200_B8","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbalip.2007.02.003","article-title":"Safety issues and prospects for future generations of PPAR modulators","volume":"1771","author":"Rubenstrunk","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"2022031302493478200_B9","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1194\/jlr.M200224-JLR200","article-title":"15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells","volume":"43","author":"Clay","year":"2002","journal-title":"J Lipid Res"},{"key":"2022031302493478200_B10","first-page":"6213","article-title":"Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation","volume":"61","author":"Palakurthi","year":"2001","journal-title":"Cancer Res"},{"key":"2022031302493478200_B11","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-5-17","article-title":"Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System","author":"Ramos-Nino","year":"2007","journal-title":"BMC Med"},{"key":"2022031302493478200_B12","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1200\/JCO.2006.07.2777","article-title":"Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes","volume":"25","author":"Govindarajan","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022031302493478200_B13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/pds.1352","article-title":"Cancer risks in thiazolidinedione users compared to other anti-diabetic agents","volume":"16","author":"Koro","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022031302493478200_B14","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2337\/dc07-2308","article-title":"Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials","volume":"31","author":"Monami","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031302493478200_B15"},{"key":"2022031302493478200_B16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/toxsci\/kfi266","article-title":"Effects of PPARgamma and combined agonists on the urinary tract of rats and other species","volume":"87","author":"Cohen","year":"2005","journal-title":"Toxicol Sci"},{"key":"2022031302493478200_B17","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"2022031302493478200_B18","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.2337\/diacare.20.9.1396","article-title":"Excess costs of medical care for patients with diabetes in a managed care population","volume":"20","author":"Selby","year":"1997","journal-title":"Diabetes Care"},{"key":"2022031302493478200_B19","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1001\/jama.287.19.2519","article-title":"Ethnic disparities in diabetic complications in an insured population","volume":"287","author":"Karter","year":"2002","journal-title":"JAMA"},{"key":"2022031302493478200_B20","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/sj.bjc.6602619","article-title":"Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies","volume":"92","author":"Huxley","year":"2005","journal-title":"Br J Cancer"},{"key":"2022031302493478200_B21","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"2022031302493478200_B22","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","article-title":"The influence of glucose-lowering therapies on cancer risk in type 2 diabetes","volume":"52","author":"Currie","year":"2009","journal-title":"Diabetologia"},{"key":"2022031302493478200_B23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.dsx.2007.11.002","article-title":"Cancer incidence among patients treated with antidiabetic pharmacotherapy","volume":"2","author":"Oliveria","year":"2008","journal-title":"Diabetes Metab Syndr"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/34\/4\/923\/607943\/923.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/34\/4\/923\/607943\/923.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T03:07:22Z","timestamp":1647140842000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/34\/4\/923\/38839\/Cohort-Study-of-Pioglitazone-and-Cancer-Incidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,21]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,3,21]]},"published-print":{"date-parts":[[2011,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc10-1067","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,21]]}}}